Clinical Edge Journal Scan

Increased risk for severe COVID-19 in rheumatoid arthritis and its phenotypic subgroups


 

Key clinical point: Patients with rheumatoid arthritis (RA), including those across different phenotypic subgroups, were at an increased risk for severe COVID-19 compared with patients without RA, with a pronounced association being observed in patients with RA-associated interstitial lung disease (RA-ILD).

Major finding: Risk for severe COVID-19 was significantly higher in patients with RA vs. those without RA (adjusted hazard ratio [aHR], 1.75; P < .0001). Risk was persistent among the sub-group of patients who were seropositive (aHR, 1.97; P < .0001) or had erosive disease (aHR, 1.93; P < .0001) and most prominent among patients with RA-ILD (aHR, 2.50; P < .0001).

Study details: Findings are from a retrospective study of 582 patients with RA and 2,875 matched comparators without RA, all of whom had COVID-19.

Disclosures: This study did not receive any funding. Some authors reported receiving research support, consulting fees, and/or grants unrelated to this study from various sources.

Source: Figueroa-Parra G et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: A retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 2022 (Sep 13). Doi: 10.1016/S2665-9913(22)00227-2.

Recommended Reading

Severe COVID-19–related outcomes found worse in men with RA
MDedge Rheumatology
Hormones’ impact described in transgender rheumatology patients
MDedge Rheumatology
Sex differences seen in inflammatory arthritis health care use
MDedge Rheumatology
Antifibrotic shows mixed results in RA-ILD
MDedge Rheumatology
Breakthrough COVID studies lend support to use of new boosters in immunosuppressed patients
MDedge Rheumatology
Evusheld PrEP may protect immunocompromised patients from severe COVID-19
MDedge Rheumatology
Previous endemic coronavirus encounters linked with long COVID
MDedge Rheumatology
Hard-rock mining and other mining work raise RA risk
MDedge Rheumatology
JAK inhibitors show no excess cardiovascular safety signal in French nationwide cohort
MDedge Rheumatology
Ten-day methotrexate pause after COVID vaccine booster enhances immunity against Omicron variant
MDedge Rheumatology